Asymptomatic Subcutaneous Semaglutide Overdose: A Case Report and Literature Review.

Diec CB, Cook EA, Nguyen NT

Journal of pharmacy practice15 Apr 2025

PMID40232990DOI10.1177/08971900251335111PepBankPUB-40232990

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanCase report or seriesSafety outcome
An 80-year-old man with type 2 diabetes who self-administered semaglutide 1 mg daily for 7 days reported no adverse drug reactions.
In plain wordsAn 80-year-old man who took semaglutide 1 mg daily for 7 days reported no side effects.
Peptide
Semaglutide
Outcome
No significant changeAny adverse drug reaction after overdose
Study
n = 1
Outcome group
Adverse events · Whole body
Studied dose
1 mg daily · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
The patient denied any ADRs, including those related to gastrointestinal upset or hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
This report describes an 80-year-old male with T2DM and mild cognitive impairment who self-administered subcutaneous semaglutide 1 mg daily over the span of 7 days.
Report a problemFND-4023299001
02HumanCase report or seriesSafety outcome
An 80-year-old man with type 2 diabetes who took semaglutide 1 mg daily for 7 days denied gastrointestinal upset.
In plain wordsAn 80-year-old man who took semaglutide 1 mg daily for 7 days reported no stomach or gut upset.
Peptide
Semaglutide
Outcome
No significant changeGastrointestinal upset after overdose
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1 mg daily · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
The patient denied any ADRs, including those related to gastrointestinal upset or hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
This report describes an 80-year-old male with T2DM and mild cognitive impairment who self-administered subcutaneous semaglutide 1 mg daily over the span of 7 days.
Report a problemFND-4023299002
03HumanCase report or seriesSafety outcome
An 80-year-old man with type 2 diabetes who took semaglutide 1 mg daily for 7 days denied hypoglycemia.
In plain wordsAn 80-year-old man who took semaglutide 1 mg daily for 7 days reported no low blood sugar.
Peptide
Semaglutide
Outcome
No significant changeHypoglycemia after overdose
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Studied dose
1 mg daily · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
The patient denied any ADRs, including those related to gastrointestinal upset or hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
This report describes an 80-year-old male with T2DM and mild cognitive impairment who self-administered subcutaneous semaglutide 1 mg daily over the span of 7 days.
Report a problemFND-4023299003
04HumanCase report or seriesEfficacy outcome
In an 80-year-old man with type 2 diabetes who took semaglutide 1 mg daily for 7 days, glucometer blood glucose readings ranged from 100 - 180 mg/dL.
In plain wordsIn one 80-year-old man who took semaglutide 1 mg daily for 7 days, home blood glucose readings stayed between 100 and 180 mg/dL.
Peptide
Semaglutide
Outcome
Not applicableBlood glucose readings after overdose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg daily · subcutaneous · 7 daysAs given in this study (human).
Measurements
Blood glucose
100 to 180 mg/dL
patient glucometer readings
Source sentences
Summary
Blood glucose readings from the patient's glucometer ranged from 100 - 180 mg/dL.
1 context sentence(design, population, supporting numbers)
Summary · context
This report describes an 80-year-old male with T2DM and mild cognitive impairment who self-administered subcutaneous semaglutide 1 mg daily over the span of 7 days.
Report a problemFND-4023299004
05HumanCase report or seriesSafety outcome
At laboratory follow-up, an 80-year-old man who took semaglutide 1 mg daily for 7 days had no clinically significant change in renal function.
In plain wordsIn one 80-year-old man who took semaglutide 1 mg daily for 7 days, kidney function showed no clinically significant change.
Peptide
Semaglutide
Outcome
No significant changeRenal function after overdose
Study
n = 1
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 mg daily · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
No clinically significant changes were noted in his renal function, hepatic function, nor his pancreatic enzymes upon laboratory follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient declined to present for medical evaluation until 5 weeks after the overdose incident.
Summary · context
This report describes an 80-year-old male with T2DM and mild cognitive impairment who self-administered subcutaneous semaglutide 1 mg daily over the span of 7 days.
Report a problemFND-4023299005
06HumanCase report or seriesSafety outcome
At laboratory follow-up, an 80-year-old man who took semaglutide 1 mg daily for 7 days had no clinically significant change in hepatic function.
In plain wordsIn one 80-year-old man who took semaglutide 1 mg daily for 7 days, liver function showed no clinically significant change.
Peptide
Semaglutide
Outcome
No significant changeHepatic function after overdose
Study
n = 1
Outcome group
Liver fat and liver function · Liver
Studied dose
1 mg daily · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
No clinically significant changes were noted in his renal function, hepatic function, nor his pancreatic enzymes upon laboratory follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient declined to present for medical evaluation until 5 weeks after the overdose incident.
Summary · context
This report describes an 80-year-old male with T2DM and mild cognitive impairment who self-administered subcutaneous semaglutide 1 mg daily over the span of 7 days.
Report a problemFND-4023299006
07HumanCase report or seriesSafety outcome
At laboratory follow-up, an 80-year-old man who took semaglutide 1 mg daily for 7 days had no clinically significant change in pancreatic enzymes.
In plain wordsIn one 80-year-old man who took semaglutide 1 mg daily for 7 days, pancreatic enzymes showed no clinically significant change.
Peptide
Semaglutide
Outcome
No significant changePancreatic enzymes after overdose
Study
n = 1
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
1 mg daily · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
No clinically significant changes were noted in his renal function, hepatic function, nor his pancreatic enzymes upon laboratory follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient declined to present for medical evaluation until 5 weeks after the overdose incident.
Summary · context
This report describes an 80-year-old male with T2DM and mild cognitive impairment who self-administered subcutaneous semaglutide 1 mg daily over the span of 7 days.
Report a problemFND-4023299007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.